(Q44863515)

6 December 2017

1 reference

title

Carcinogenic human papillomavirus infection (English)

1 reference

6 December 2017

4

Silvia de Sanjosé

0 references

Silvia Franceschi

object named as

Silvia Franceschi

series ordinal

8

0 references

Nicolas Wentzensen

series ordinal

3

object named as

Nicolas Wentzensen

1 reference

6 December 2017

1

Mark Schiffman

1 reference

6 December 2017

2

John Doorbar

1 reference

6 December 2017

6

Bradley J Monk

1 reference

6 December 2017

Carole Fakhry

5

1 reference

6 December 2017

Margaret A Stanley

series ordinal

7

1 reference

6 December 2017

publication date

1 December 2016

1 reference

Nature Reviews Disease Primers

6 December 2017

published in

1 reference

6 December 2017

volume

2

1 reference

6 December 2017

page(s)

16086

1 reference

Papillomaviruses: Viral evolution, cancer and evolutionary medicine

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evolution of the papillomaviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Comprehensive control of human papillomavirus infections and related diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Global burden of cancers attributable to infections in 2012: a synthetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Role of Human Papillomavirus in Penile Carcinomas Worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cancers attributable to infections among adults with HIV in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Role of human papillomavirus in non-oropharyngeal head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Clinical trials of human papillomavirus vaccines and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Epidemiology of oral human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Prevalence of oral HPV infection in the United States, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The cervical cancer epidemic that screening has prevented in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Time since first sexual intercourse and the risk of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Estrogen and ERalpha: culprits in cervical cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The biology and life-cycle of human papillomaviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Arrangement of L2 within the papillomavirus capsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Molecular biology of human papillomavirus infection and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Regulatory elements in the viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Papillomavirus transcripts and posttranscriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Papillomavirus E6 and E7 proteins and their cellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The papillomavirus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Establishment of human papillomavirus infection requires cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Latent papillomavirus infections and their regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus E6/E7 oncogenes promote mouse ear regeneration by increasing the rate of wound re-epithelization and epidermal growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Different modes of human papillomavirus DNA replication during maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Papillomavirus genome structure, expression, and post-transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Regulation of the human papillomavirus type 16 late promoter by E7 and the cell cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Papillomavirus E6 oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The papillomavirus E7 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Type-dependent integration frequency of human papillomavirus genomes in cervical lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

APOBEC3A functions as a restriction factor of human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Viral oncoproteins target the DNA methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Transcriptional repression of E-cadherin by human papillomavirus type 16 E6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Epithelial cell responses to infection with human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Ubiquitin in the activation and attenuation of innate antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

High-risk human papillomavirus targets crossroads in immune signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Interferon Kappa Inhibits Human Papillomavirus 31 Transcription by Inducing Sp100 Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus type 8 interferes with a novel C/EBPβ-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Immunosuppression facilitates the reactivation of latent papillomavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Altered α-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The role of sex hormones in immune protection of the female reproductive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Estrogen receptors regulate innate immune cells and signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus vaccines--immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Immunogenicity and safety of the 9-valent HPV vaccine in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Gavi HPV Programs: Application to Implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A review of clinical trials of human papillomavirus prophylactic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Comparing the performance of six human papillomavirus tests in a screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Triage of HPV positive women in cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Interobserver agreement in the assessment of components of colposcopic grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Number of cervical biopsies and sensitivity of colposcopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Multiple biopsies and detection of cervical cancer precursors at colposcopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evaluating HPV-negative CIN2+ in the ATHENA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

2011 terminology of the vulva of the International Federation for Cervical Pathology and Colposcopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Screening to prevent anal cancer: Current thinking and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Improved survival with bevacizumab in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Chemoradiotherapy for anal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Anal cancer: current standards in care and recent changes in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Oropharyngeal cancer survivorship in Denmark, 1977-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Rising population of survivors of oral squamous cell cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Enhanced radiation sensitivity in HPV-positive head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Head and Neck Cancers, Version 1.2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomaviruses: genetic basis of carcinogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A review of human carcinogens--Part B: biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus infection and the multistage carcinogenesis of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Sexual behaviour in context: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Soil-Transmitted Helminth Infections Are Associated With an Increase in Human Papillomavirus Prevalence and a T-Helper Type 2 Cytokine Signature in Cervical Fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A single type of progenitor cell maintains normal epidermis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Why do human papillomavirus infections induce sharply demarcated lesions of the cervix?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Mucosal junctions: open doors to HPV and HIV infections?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Heterogeneity in CIN3 diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

High-resolution anoscopy screening of HIV-positive MSM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Evidence-based therapy for recurrent cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.86

31 March 2020

Identifiers

DOI

10.1038/NRDP.2016.86

1 reference

6 December 2017

1 reference